Prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: A randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer (KSCC1402/HGCSG1402)
Oncology Mar 10, 2018
Tanioka H, et al. - Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or malaise was investigated. The clinical efficacy of prophylactic oral DEX in improving regorafenib-related fatigue and/or malaise was demonstrated.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries